Neuronoff, Inc.

Neuronoff, Inc. is a medical device company focused on developing neuromodulation technologies to restore and improve organ activity, particularly in the treatment of chronic pain. Based in the United States, the company employs between 11 and 50 people. The flagship product, the Injectrode® Platform, is a minimally invasive, injectable electrode designed to relieve chronic pain without drugs or invasive surgeries. This device is implanted using a simple needle-based procedure, allowing for quick placement and minimal skin puncture. The Injectrode targets peripheral nerve branches, especially in the lumbar lower back, providing a discreet alternative to traditional neuromodulation therapies. Neuronoff's technology has shown safety and effectiveness in successful first-in-human studies, positioning it as a promising option for patients seeking non-pharmacological pain management solutions. The company is led by CEO Manfred Franke, who has extensive experience in neuromodulation research and device development.

• Employees20
• Founded2017
• Annual Revenue$2500000
• Total Funding$11700000